Eloxx Pharmaceuticals, Inc.
ELOXD
OTC PK
| 03/31/2026 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 200.00% | -31.87% | -34.68% | -28.79% | -55.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.56% | -59.79% | -49.94% | -48.17% | -30.29% |
| Operating Income | -210.56% | 59.79% | 49.94% | 48.17% | 30.29% |
| Income Before Tax | -119.66% | 59.12% | 46.39% | 47.73% | 24.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -119.66% | 59.12% | 46.39% | 47.73% | 24.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -119.66% | 59.12% | 46.39% | 47.73% | 24.05% |
| EBIT | -210.56% | 59.79% | 49.94% | 48.17% | 30.29% |
| EBITDA | -- | 59.82% | 49.98% | 48.13% | 30.31% |
| EPS Basic | 82.66% | 59.97% | 46.39% | 47.78% | 24.44% |
| Normalized Basic EPS | 82.40% | 59.97% | 49.88% | 47.78% | 28.35% |
| EPS Diluted | 82.66% | 59.97% | 46.39% | 47.75% | 24.34% |
| Normalized Diluted EPS | 82.40% | 59.97% | 49.88% | 47.78% | 28.35% |
| Average Basic Shares Outstanding | 1,166.84% | 2.12% | 0.00% | 0.09% | 0.52% |
| Average Diluted Shares Outstanding | 1,166.84% | 2.12% | 0.00% | 0.09% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |